Oncolytics Biotech Inc. (ONCY): Price and Financial Metrics
ONCY Price/Volume Stats
| Current price | $1.64 | 52-week high | $2.28 |
| Prev. close | $1.72 | 52-week low | $0.80 |
| Day low | $1.58 | Volume | 440,500 |
| Day high | $1.74 | Avg. volume | 220,201 |
| 50-day MA | $1.44 | Dividend yield | N/A |
| 200-day MA | $1.50 | Market Cap | 105.11M |
ONCY Stock Price Chart Interactive Chart >
Oncolytics Biotech Inc. (ONCY) Company Bio
Oncolytics Biotech Inc. discovers and develops pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics. The Company is focusing on the development of the reovirus known as REOLYSIN as a potential cancer therapeutic.
Latest ONCY News From Around the Web
Below are the latest news stories about ONCOLYTICS BIOTECH INC that investors may wish to consider to help them evaluate ONCY as an investment opportunity.
Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response RateOncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced updated results from BRACELET-1, a randomized phase 2 trial in HR+/HER2- metastatic breast cancer, which include data featured in an oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, as well as additional new data and analyses. |
Oncolytics Biotech® to Host Key Opinion Leader Webinar on Data from the Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer Being Presented at the Upcoming ASCO Annual MeetingOncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) announced that it will host a key opinion leader webinar to discuss data from the randomized phase 2 BRACELET-1 trial in HR+/HER2- metastatic breast cancer, which will be featured in an oral presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting. The webinar will take place on Monday, June 5, 2023 at 8:00 a.m. ET. |
Oncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives ≥50% Improvements in ORR and mPFS in an ASCO Annual Meeting AbstractOncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced positive results from BRACELET-1, a randomized phase 2 trial in HR+/HER2- metastatic breast cancer. The results are published in an abstract accepted for an oral presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from June 2 – 6, 2023 in Chicago, Illinois and online. The abstract is available on the ASCO Annual Meeting website. |
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of ShareholdersOncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Tuesday, May 9, 2023. A total of 44% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting. |
Oncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2023 Earnings Call TranscriptOncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2023 Earnings Call Transcript May 5, 2023 Operator: Good morning. And welcome to Oncolytics Biotech’s First Quarter 2023 Conference Call. All participants are now in listen-only mode. There will be a question-and-answer session at the end of this call. Please be advised that this call is being recorded at the […] |
ONCY Price Returns
| 1-mo | 2.50% |
| 3-mo | 17.14% |
| 6-mo | -4.65% |
| 1-year | 60.78% |
| 3-year | -22.64% |
| 5-year | -77.22% |
| YTD | 0.61% |
| 2022 | 17.27% |
| 2021 | -41.60% |
| 2020 | -50.00% |
| 2019 | 162.98% |
| 2018 | -66.46% |
Loading social stream, please wait...